Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study

N. Eaton-Fitch1,2,3 · S. C. Johnston1,2,3 · P. Zalewski3,4 · D. Staines2,3 · S. Marshall-Gradisnik2,3

Abstract

Background Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious and debilitating disorder associated with significant disruptions in daily life including. This study aimed to examine the impact of sociodemographic and patient symptom characteristics on health-related quality of life (HRQoL) of Australians with ME/CFS.

Methods Self-reported data collected from 480 individuals diagnosed with ME/CFS were obtained between August 2014 and August 2018. This cross-sectional survey analysed sociodemographic, symptom characteristics and HRQoL according to the 36-Item Health Survey (SF-36). Multivariate linear regression models were used to determine ME/CFS symptoms associated with eight domains of HRQoL.

Results Reported HRQoL was significantly impaired in ME/CFS patients across all domains compared with the general population. Scores were the lowest for physical role (4.11 ± 15.07) and energy/fatigue (13.54 ± 13.94). Associations with females, higher body mass index (BMI), employment status, cognitive difficulties, sensory disturbances and cardiovascular symptoms were observed in the physical functioning domain. Impaired pain domain scores were associated with high BMI, annual visits to their general practitioner, flu-like symptoms and fluctuations in body temperature. Reduced well-being scores were associated with smoking status, psychiatric comorbidity, cognitive difficulties, sleep disturbances and gastrointestinal difficulties.

Conclusion This study provides evidence that ME/CFS has a profound and negative impact on HRQoL in an Australian cohort.

Keywords Myalgic encephalomyelitis · Chronic fatigue syndrome · Health-related quality of life · SF-36

Introduction

Myalgic encephalomyelitis (ME), also referred to as chronic fatigue syndrome (CFS), is a serious condition clinically defined by dysregulation of the central nervous, cardiovascular and immune systems, endocrine dysfunction, and impaired cellular energy metabolism and ion transport [1, 2]. Due to the ambiguous nature of ME/CFS, there is no single diagnostic test; however, diagnosis relies on the fulfilment of criteria after unsuccessful differential diagnosis. In 1994, the Centers for Disease Control and Prevention (CDC) published the Fukuda Criteria to evaluate and classify ME/CFS patients and provide a basis for diagnosis [3]. A case of ME/CFS is defined under these criteria by the presence of unexplainable chronic fatigue that is not alleviated by rest. Furthermore, at least four additional concurrent symptoms including sore throat, tender lymph nodes, muscle and/or joint pain, impaired cognition and
sleep disturbances are necessary for diagnosis. Revised protocols birthed the Canadian Consensus Criteria (CCC) (2003) and the International Consensus Criteria (ICC) (2011) [1, 4]. These revised definitions introduced the following symptoms post-exertional neuromuscular exhaustion accompanied by numerous neurological, cardiovascular, autonomic and neuroendocrine manifestations.

The prevalence of ME/CFS is difficult to determine due to the absence of a diagnostic test; however, estimates believe that 200,000 Australians have been diagnosed or report symptoms of ME/CFS [5]. Epidemiological studies have commented on the severity spectrum of ME/CFS. Patient severity is defined by a significant reduction in the patient’s premorbid activity level. Mild patients self-report an approximately 50% reduction in pre-illness activity level including ability to maintain employment and social interactions. Approximately 25% of ME/CFS patients are considered severe, being primarily bed-bound, while moderate patients are bound to their home [6]. Relatively few patients with ME/CFS completely recover [7], with a recovery rate below six% and increased disability in 10–20% of patients over time [8].

The Medical Outcomes Study Short-Form General Health Survey (SF-36) is widely used to measure self-reported health-related quality of life (HRQoL) [9, 10]. Previous qualitative investigations have used SF-36 to report distinctive patterns of impairment in ME/CFS patients and to distinguish these patients from other conditions. The SF-36 consists of domains separately referred to as physical functioning, physical role, body pain, general health, social functional, emotional health and fatigue/energy. A previous investigation by Reeves et al. defined SF-36 scores in mild, intermediate and severe ME/CFS patients [11]. According to this empiric ME/CFS case definition, the disability criterion is met by scoring the 25th percentile on any one of the following four SF-36 scales: Physical Functioning (≤ 70), Physical Role (≤ 50), Social Functioning (≤ 75) or Emotional Role (≤ 66.7) [11].

HRQoL is an important assessment in chronic conditions to monitor disability as a predictor of health service requirements [12]. The aim of this study was to further understand contributions of ME/CFS pathophysiology associated with reduced HRQoL and identify aspects of health that are most limited. We hypothesise that particular sociodemographic and symptom characteristics would be associated with significantly reduced HRQoL. Identifying these symptoms may improve patient management and health resource allocation.

Method

Study design and setting

This study utilises a cross-sectional survey during a four-year period from August 2014 to August 2018 that collected patient level data for biological investigations into ME/CFS at NCNED (National Centre for Neuroimmunology and Emerging Diseases) research centre. ME/CFS patients across Australia volunteered in this survey in response to online recruitment advertisements. To be eligible for this study, participants were required to: (1) report experiencing ME/CFS illness; (2) be between 18 and 65 years of age; and (3) be a resident of Australia. Informed consent was obtained by agreeing to terms and conditions disclosed online or signing a hard copy sent via email. This study was approved by Griffith University Human Research Ethics Committee (HREC reference: MSC0413).

Data collection

Participants completed a survey through an online application (LimeSurvey, Carsten, Schmitz, Hamburg, Germany) or by hard copy in the mail. Data from completed hard copy questionnaires were returned to NCNED and manually entered into LimeSurvey by a member of the research team. Items in the survey were developed by the authors and items included sociodemographic details, a 60-item checklist on fatigue and ME/CFS symptoms repurposed from the Fukuda [3], CCC [4] and ICC [1] diagnostic definitions. Participants were asked to disclose other illnesses as diagnosed by a physician and medications routinely administered within two weeks of completing the questionnaire. All participants were anonymised using an alpha-numeric code.

Sociodemographic characteristics

Sociodemographic data were collected. Age was measured at time of response and gender (male or female). Body Mass Index (BMI, kg/m²) was calculated by participants according to self-reported weight (kg) and height (cm). BMI was used to categorised participants as underweight (< 18.5), normal (18.5–24.9), overweight (25.0–29.9) and obese (> 30.0). Participants reported their highest level of education obtained and assessed according to primary school, high school, professional training, undergraduate degree or postgraduate degree. Participants reported their working status and was analysed as full time, part time, disability pension, retired or unemployed. Smoking status was reported as either smoker or non-smoker.

Psychological comorbidity was assessed according to whether a participant reported concurrent diagnosis of a psychological condition by a physician (e.g. depression and anxiety). Participants reported the number of visits to a general practitioner per. Participants were also asked whether they identified with an infectious event such as cold, flu, bacteria or viral infection prior to the onset of their illness and examined according to ‘yes’ or ‘no’ responses. Age of onset,
defined as age the participant noticed ME/CFS symptoms had caused a disruption to daily or vocational activities.

**Symptom characteristics**

To coincide with the study measures of HRQoL, this investigation asked participants to also report the impact of seven symptom categories during the past four weeks. These categories included the following: (i) cognitive difficulties (slowed thought, impaired concentration and short term memory loss); (ii) pain (headaches, muscle pain and multijoint pain); (iii) sleep disturbances (insomnia, prolonged sleep, reversed sleep cycle); (iv) cardiovascular symptoms (orthostatic intolerance, heart palpitations, light headedness and dizziness); (v) respiratory symptoms (air hunger, laboured breathing); (vi) body temperature intolerances (subnormal body temperature, abnormal sweating episodes, hot flushes and cold extremities); and (vii) sensory, perceptual and motor disturbances (sensitivity to touch, light, odour, taste, sound, movement, and poor balance or coordination). Symptom severity was measured by four-point scale corresponding to non, mild, moderate to severe and was analysed dichotomously as non-mild vs. moderate–severe.

Participants reported symptoms and illnesses were reviewed by the authors of this manuscript to exclude any potential major illnesses reported as active, recurrent or not completely resolved, as this may be an alternative explanation for symptoms. Other diagnoses leading to exclusion include, but not limited to the following: thyroid-related diseases, high BMI, diabetes, insomnia, cardiovascular disease, autoimmune diseases or malignancies. To be included in this study, participants were required to fulfil the Fukuda case definition [3]. To fulfil this criteria fatigue was required to be present for at least six months leading to a significant disruption to daily and vocational activities. Additionally, this fatigue must have been accompanied by at least four of the following symptoms: (i) post-exertional malaise; (ii) cognitive difficulties; (iii) headache; (iv) sore throat; (v) muscle pain; (vi) multi-joint pain; (vii) unrefreshing sleep and (viii) tender lymph nodes. Accompanying symptoms should not have preceded the onset of fatigue and also be persistent or recurring for at least 6 months.

**Health-related quality of life**

HRQoL was measured according to the SF-36 Item Health Survey version 1.0 [12]. The survey contains 36 items to measure physical health and mental health of participants during a four-week period. The SF-36 survey is divided into eight domains including: (i) physical functioning; (ii) role limitations due to physical health; (iii) role limitations due to pain; (iv) role limitations due to general health; (v) role limitations due to emotional health; (vi) role limitations due to vitality; (vii) role limitations due to emotional well-being and (viii) role limitations due to social functioning. Each item was assessed by Likert scales, with each response assigned a value ranging from 0 to 100. Scores from each domain were averaged to provide a final score with lower scores indicating reduced HRQoL and high scores indicating better HRQoL. General population SF-36 scores were obtained from the Australian Bureau of Statistics 1995 National Health Survey for comparison with ME/CFS patients [13]. The authors wish to note that more recent data specific to SF-36 general population scores are not available for this comparison.

**Statistical analysis**

Statistical analysis was performed to examine ME/CFS symptoms associated with each HRQoL domain from the following categories: (i) physical functioning; (ii) role limitations due to physical health; (iii) role limitations due to pain; (iv) role limitations due to general health; (v) role limitations due to emotional health; (vi) role limitations due to energy/fatigue; (vii) role limitations due to emotional well-being and (viii) role limitations due to social functioning. Multivariate analysis was performed (multi linear regression) using the forward stepwise procedure to determine our final models for each HRQoL domain. Age, sex (male vs. female) and BMI (underweight < 18.5; normal 18.5–24.9; overweight 25.0–29.9; and obese > 30.0) were adjusted over weight 25.0–29.9; and obese > 30.0) were adjusted in each model prior to analysis and included in analysis irrespective of significance. The Akaike information criteria (AIC) were used to compare regression models and the model with the smallest AIC value was used. Thus, all other health variables were included as variables if \( p < 0.1 \). We verified basic assumptions for multiple linear regression including normality of residuals and report standardised beta (\( \beta \)) coefficients, with corresponding \( t \) and \( p \) values. Robustness checks were performed using ordinal logistic regression and due to the non-normal nature of the data, quantile regression was also performed. Any discrepancies in results obtained from these models were recorded in the results. All data presented are mean ± standard deviation (SD) unless otherwise stated. The analysis was conducted using SPSS v.24 software (IBM Corp, USA) and STATA v.14 (StataCorp, Texas, USA).

**Results**

**Patient demographics**

During the study period of August 2014 to August 2018, 480 ME/CFS patients successfully completed and submitted the questionnaire. All patients reported symptoms fulfilling the
Fukuda criteria and no other fatigue related illnesses that may account for their symptoms. Table 1 includes all demographic data of Australian ME/CFS patients who completed the questionnaire. The sample was predominantly female (77.5%), within normal BMI (18.5–24.9) range (45.5%), received the disability pension (28.8%), completed an undergraduate degree (31.3%) and resided in Queensland (44%). Majority of participants identified themselves as non-smokers (90.8%). Approximately half the sample reported experiencing the onset of their symptoms prior to age 30 (49.0%) in addition to reporting undue stress (52.5%) and an infectious event prior to onset (48.3%).

Table 2 includes all ME/CFS symptom descriptive data and associated severity scores. During the 30 days prior to completing the survey, many participants reported experiencing moderate to severe cognitive difficulties (75%), pain (72.3%), and sleep disturbances (73.3%). Approximately half reported experiencing moderate to severe sensory disturbances (56.3%), flu-like symptoms such as sore throat, tender lymph nodes, and sinus issues (53.8%), gastrointestinal disturbances (55.2%) and problems with body temperature (51.7%). A proportion reported experiencing moderate to severe cardiovascular symptoms (19.2%) and breathing difficulties (30.0%).

HRQoL scores in ME/CFS patients compared with general population

General population scores were obtained from the Australian Bureau of Statistics 1995 National Health Survey [13]. This survey presents an overview of health status (e.g. prevalence of disease) and factors which may influence health (e.g. smoking, exercise). The majority of Australians considered themselves as being in good health with 83% reporting their health status as good, very good or excellent. Three-quarters of the population experience one or more long-term condition lasting six months or longer. Common illnesses reported in the general population include asthma (11%), headache (13%), hypertension (10%), short sighted (21%) and arthritis (15%).

The SF-36 health outcomes survey was used to assess HRQoL in ME/CFS patients compared with general population norms for Australians. As reported in Table 3, mean HRQoL scores were significantly reduced in ME/CFS patients across all domains ($p < 0.001$). Scores were particularly low for limitations due to physical health (4.11 ± 15.1) and energy/fatigue (13.54 ± 13.94).

Symptom and health characteristic HRQoL scores for ME/CFS patients

Multivariate analyses for HRQoL domains including physical functioning, physical role, pain and general health

---

Table 1 | ME/CFS Descriptive characteristics ($n=480$)

| Category                  | Count ($n$) | Percentage |
|---------------------------|-------------|------------|
| Age (years, mean ± SD)    | 46.0 ± 12.3 |
| Gender (n, %)             |             |            |
| Female                    | 372         | 77.5%      |
| Male                      | 108         | 22.5%      |
| BMI (n, %)                |             |            |
| Underweight < 18.5        | 18          | 3.8%       |
| Normal 18.5–24.9          | 218         | 45.4%      |
| Overweight 25.0–29.9      | 128         | 26.7%      |
| Obese > 30                | 116         | 24.2%      |
| Work status (n, %)        |             |            |
| Full time                 | 88          | 18.3%      |
| Part time                 | 105         | 21.9%      |
| Retired                   | 15          | 3.1%       |
| Unemployed                | 134         | 27.9%      |
| Disability pension        | 138         | 28.8%      |
| Education (n, %)          |             |            |
| Primary school            | 3           | 0.6%       |
| High school               | 108         | 22.5%      |
| Professional training     | 110         | 22.9%      |
| Undergraduate             | 150         | 31.3%      |
| Postgraduate              | 109         | 22.7%      |
| Smoking status (n, %)     |             |            |
| Smoking                   | 44          | 9.2%       |
| Non-smoking               | 436         | 90.8%      |
| Location (n, %)           |             |            |
| Queensland                | 211         | 44%        |
| New South Wales           | 103         | 21.5%      |
| Victoria                  | 71          | 14.9%      |
| ACT                       | 8           | 1.8%       |
| Northern Territory        | 2           | 0.4%       |
| South Australia           | 24          | 5.0%       |
| Western Australia         | 38          | 7.9%       |
| Tasmania                  | 9           | 1.9%       |
| Psychological comorbidity (n, %) | 77 | 16.1% |
| No                        | 400         | 83.9%      |
| WHODAS                    |             |            |
| Communication and understanding | 35.58 ± 18.13 |
| Mobility                  | 43.32 ± 22.43 |
| Self-Care                 | 17.53 ± 19.73 |
| Getting along             | 32.74 ± 22.98 |
| Life activities           | 56.64 ± 27.43 |
| Participation in work/school | 58.40 ± 27.26 |
| Participation in society  | 48.61 ± 22.43 |
| GP visits per year (mean ± SD) | 12.0 ± 16.2 |
| Onset age (mean ± SD)     | 29.9 ± 12.1 |
| Infection onset (n, %)    |             |            |
| Yes                       | 232         | 48.3%      |
| No                        | 248         | 51.7%      |
| Undue stress onset (n, %) |             |            |
| Yes                       | 252         | 52.5%      |
are presented in Table 4. Significantly reduced scores for physical functioning were associated with individuals that were female, had a higher BMI, employment status and cognitive difficulties, sensory disturbances and cardiovascular symptoms. These factors explained 23.6% of total variance (adjusted $R^2 = 0.236$, $p < 0.001$). Significantly reduced scores for role limitations due to physical health were associated with annual visits to the GP, severe pain symptoms, cognitive disturbances and gastrointestinal disturbances (adjusted $R^2 = 0.075$, $p < 0.001$). Significantly reduced scores for pain were associated with higher BMI, employment status, annual visits to the GP, pain symptoms, flu-like or immunological symptoms, and body temperature complaints (adjusted $R^2 = 0.497$, $p < 0.001$). The factors associated with significantly reduced general health scores were associated with higher BMI, psychological comorbidities, smoking status, sensory disturbances and gastrointestinal symptoms (adjusted $R^2 = 0.086$, $p < 0.001$).

Table 5 shows the results of multivariate analyses for HRQoL domains including social functioning, energy/fatigue, emotional role and well-being. Significantly reduced scores for social functioning were associated with employment status, psychological comorbidities, cognitive difficulties, sensory disturbances and cardiovascular symptoms (adjusted $R^2 = 0.13$, $p < 0.001$). Significantly reduced scores for energy/fatigue were associated with higher BMI, smoking status and flu-like symptoms (adjusted $R^2 = 0.086$, $p < 0.001$). The factors associated with reduced scores for role limitations due to emotional health were psychological comorbidity, annual GP visits, cognitive difficulties and body temperature complaints (adjusted $R^2 = 0.045$, $p < 0.001$). Significantly reduced scores for general well-being were associated with higher age, psychological comorbidity, smoking status, cognitive difficulties, sleep disturbances and gastrointestinal disturbances ($R^2 = 0.155$, $p < 0.001$).
Table 4  Multivariate analysis of HRQoL physical functioning, physical role, pain and general health domains

|                      | Physical functioning | Physical role | Pain       | General health |
|----------------------|----------------------|---------------|------------|---------------|
|                      | \( \hat{\beta} \)  | \( T \)  | \( P \)  | \( \hat{\beta} \) | \( t \) | \( p \)  | \( \hat{\beta} \) | \( t \) | \( p \)  | \( \hat{\beta} \) | \( t \) | \( p \)  |
| Age                  | -0.044               | -1.076        | 0.283      | -0.086        | -1.908 | 0.057 | -0.03 | -0.896 | 0.371 | 0.071 | 1.56 | 0.119 |
| Gender               | -0.156               | -3.809        | <0.001     | -0.007        | -0.155 | 0.877 | 0.002 | 0.07 | 0.945 | -0.05 | -1.128 | 0.26 |
| BMI                  | -0.100               | -2.434        | 0.015      | -0.009        | -0.197 | 0.844 | -0.089 | -2.652 | 0.008 | -0.087 | -1.885 | 0.06 |
| Work status          | -0.190               | -4.615        | <0.001     |                        |         |       | -0.058 | -1.759 | 0.079 |                        |         |       |
| Education            |                       |               |           | Psychological comorbidity | -0.077 | -1.684 | 0.093 |                        |         |       |
| Smoking status       |                       |               |           | Smoking status | -0.088 | -1.947 | 0.052 |                        |         |       |
| Infectious onset     |                       |               |           | Infectious onset |         |       |       |       |       |       |       |
| GP visits per year   |                       |               |           | GP visits per year | -0.074 | -1.655 | 0.099 | -0.071 | -2.117 | 0.035 |       |       |
| Onset age            |                       |               |           | Onset age | -0.23 | -5.142 | <0.001 | -0.078 | -1.701 | 0.09 | -0.639 | -18.711 | <0.001 |
| Cognition            | -0.106               | -2.455        | 0.014      | -0.23        | -5.142 | <0.001 | -0.078 | -1.701 | 0.09 | -0.639 | -18.711 | <0.001 |
| Pain                 | -0.193               | -4.720        | <0.001     | -0.093        | -2.061 | 0.04 | -0.072 | -2.095 | 0.037 | -0.181 | -3.944 | <0.001 |
| Sleep                |                       |               |           | Sleep | -0.228 | -5.0273 | <0.001 |                        |         |       |
| Sensory              |                       |               |           | Sensory | -0.114 | -2.489 | 0.013 |                        |         |       |
| Flu                  |                       |               |           | Flu | -0.181 | -3.944 | <0.001 |                        |         |       |
| Gastrointestinal     |                       |               |           | Gastrointestinal | -0.093 | -2.061 | 0.04 | -0.072 | -2.117 | 0.035 |                        |         |       |
| Cardiovascular       |                       |               |           | Cardiovascular | 0.247 | 0.099 | 0.505 | 0.099 |                        |         |       |
| Respiratory          |                       |               |           | Respiratory | 0.236 | 0.085 | 0.497 | 0.086 |                        |         |       |
| Temperature          |                       |               |           | Temperature | <0.001 | <0.001 | <0.001 | <0.001 |                        |         |       |

\( HRQoL \) health-related quality of life, \( BMI \) body mass index, \( GP \) general practitioner
Robustness check

Due to the nature of some survey responses and the non-normal nature of the data, robustness checks were performed. Differences in statistical significance were reporting for the following using quantile regression: (i) a loss of significance for cognitive difficulties was reported for physical functioning; (ii) for pain a statistical significance was lost for BMI, employment status, annual visits to the GP and temperature instability; (iii) for general health statistical significance was lost for age; (iv) statistical significance was lost for employment status for social functioning; (v) for energy/fatigue a loss of significance was reported for gender, age and smoking status and (vi) for role emotional statistical significance was lost for annual visits to the GP. Ordinal logistic regression was also performed and differences in statistical significance were reported for the following: (i) for physical role statistical significance was lost for age and (ii) for pain statistical significance was lost for employment status.

Discussion

The present findings represent the largest and most recent investigation of an Australian population for physical and mental health status reported by those experiencing ME/CFS symptoms. This current manuscript for the first time reports important factors to consider in improving patient outcomes and overall HRQoL. Consistent with other investigations, HRQoL outcomes were significantly reduced in ME/CFS patients compared with general population norms. A previous Australian pilot study completed at NCNED compared HRQoL between individuals diagnosed using the Fukuda criteria and a subset that also fulfilled the ICC [14]. Expectedly, those fulfilling the ICC reported significantly reduced HRQoL scores compared with ME/CFS patients diagnosed using the Fukuda criteria. This current investigation uses a large sample size to provide a statistical overview of HRQoL outcomes for Australian ME/CFS patients.
SF-36 has been recommended as a sufficient measure to determine substantial reductions in HRQoL. Reeve’s empirical ME/CFS case definition recommends scores below the 25th percentile of any of the four mentioned subscales including: (i) Physical Functioning ≤ 70; (ii) Role Physical ≤ 50; (iii) Role Emotional ≤ 66.7 and (iv) Social Functioning ≤ 75 [11]. A review by Jason and colleagues reported that the SF-36 scales have adequate discrimination between ME/CFS patients and healthy individuals following Reeve’s empirical cut-off scores [15]. While Role Emotional was reported to have the worst sensitivity and specificity for ME/CFS patients, Role Physical (≤ 50), Social Functioning (≤ 62.5) and Energy/Fatigue (≤ 35) had the best sensitivity and specificity [15]. In this present investigation, few participants did not fall within these cut-offs with 11.4% obtained Social Functioning scores ≤ 62.5, 10.4% obtained Energy scores ≤ 35 and 3.5% obtained role physical scores ≤ 50.

In this investigation, low HRQoL scores were correlated with unemployment, cognition deficits in severe patients, sensory and sleep disturbances, flu-like symptoms and cardiovascular symptoms. Cognitive difficulties, pain and sleep disturbances were reported as the most common symptom amongst ME/CFS patients. We also report that physical role was significantly correlated with mental cognition, pain and gastrointestinal upset. This investigation included a higher number of females, which has been a common observation in numerous epidemiological studies and not a limitation in this current study [16–20]. We found the females reported significantly reduced scores for physical functioning and energy/fatigue; however, scores for other domains were not significant between genders. As expected, lower scores of HRQoL were observed in ME/CFS patients who more frequently visit their general practitioner. Patient reported outcome measures in clinical practice, in particular those evaluating HRQoL, have been proposed as a means of facilitating doctor-to-patient communication, understanding patient complaints, monitoring symptoms or treatment and screening for functioning problems [21].

In this present investigation, 56.7% of ME/CFS patients were unemployed, with half receiving government issued disability payments. This is consistent with a previous investigation by Nijs and colleagues who reported a significant association between self-reported employment status and physical functioning as well as social functioning [22]. In this report, of the 54 ME/CFS patients, 50% received financial disability compensation. Low employment rates are believed to contribute to the economic burden imposed by ME/CFS [23]. Using archival data from USA, Jason and colleagues reported that the annual direct cost per ME/CFS patient was estimated between US$2,342 and US$8,675 [24]. The total costs associated with ME/CFS was approximately US$17–24 billion annually taking into consideration loss of productivity, salary variables, cost of health care providers and increased government issued disability payments.

Higher BMI had a significant impact on physical functioning, pain, general health, as well as energy/fatigue scores. The authors would like to note that physicians and patients need to carefully consider the management of physical activity to improve BMI in ME/CFS patients. Previous investigations have reported a marked onset of fatigue and poor recovery in ME/CFS patients following physical activity [1, 25]. ME/CFS patients suffer from exacerbated fatigue following physical exertion and can exercise less often and to a lesser intensity than healthy controls [22]. Few studies have examined the association of weight gain/obesity with ME/CFS. Flores and colleagues reported that overweight/obese ME/CFS patients had significantly reduced SF-36 disability outcomes [26]. Therefore, comorbid weight has consequences on physical functioning and HRQoL subsets. Impaired physical functioning and severe post-exertional malaise may contribute to inactivity as physical functioning was also associated with cardiovascular complaints.

Our findings are consistent with large studies published from the United States of America (USA), Denmark and United Kingdom [22, 27–32]. A Danish study demonstrated that HRQoL scores among those with ME/CFS were significantly reduced compared with the general population norms as well as 20 other chronic conditions including rheumatoid arthritis, numerous malignancies, angina and ischemic stroke, pulmonary disease and multiple sclerosis [32], while a study published from the United Kingdom reported significantly reduced HRQoL scores in ME/CFS patients compared to the general population in addition to other chronic conditions including depression, cancer and rheumatoid arthritis [27]. This publication also reported reduced HRQoL scores in ME/CFS patients defined using the CCC in comparison with the Fukuda criteria [27]. This is believed to be attributed to additional symptoms required to meet the CCC and ICC criteria. The Fukuda case definition is a limiting factor as symptoms are not specific, whereas the CCC and ICC definitions are highly specific for ME/CFS and encompasses more symptom categories.

The pathophysiology and aetiology of ME/CFS remain unknown resulting in diagnostic ambiguity and difficulty [33]. Without a clear understanding of the pathophysiology, no internationally recognised treatment exists, and current medical interventions focus on symptom management. A review by Bested and Marshall on the diagnosis and management of ME/CFS patients reported an estimate that only 20% of individuals with ME/CFS have been formally diagnosed and fewer have received expert medical advice [34]. There is evidence to suggest different phenotypes or profiles may explain variability between patients [35]. As this study provides evidence of the disabling effects of ME/CFS and impaired quality of life, this evidence hopes to motivate the
Australian public health community. We believe this study represents the need for renewed public health policy leading to increased research outputs and thus patient care.

This publication is not without limitations: firstly, the recruitment method for this investigation was based on self-identification in response to NCNED advertisements. It is therefore unknown how many active members were potentially eligible for the study and the rate of non-responders is unable to be determined. Secondly, the survey used for this investigation is limited by self-reporting of medical history and symptoms. Third, due to the cross-sectional design of this investigation, it is also not possible to make causal inference between the examined symptoms and HRQoL domains. Prospective studies of this cohort in the future may provide further evidence towards the aetiology of ME/CFS. Fourth, the authors note that a number of HRQoL domains had lower explanatory power, however, remained statistically significant ($p \leq 0.001$). Future research will investigate the effect of additional clinical variables, such as disease stage, symptom severity and comorbidities to gather additional information to include in our model. Fourth, data obtained during this investigation were compared to healthy population norms released 25 years ago. Finally, during symptom analysis data were categorised dichotomously as either none-mild or moderate-severe. Therefore, variation for symptom severity in ME/CFS patients may be further assessed for future investigations by categorising ME/CFS patient symptoms as either none, mild, moderate or severe.

**Conclusion**

While numerous publications have reported on HRQoL outcomes for ME/CFS patients, there is limited literature using Australian patients. All ME/CFS patients included in this investigation met the Fukuda diagnostic criteria for ME/CFS and reported significantly reduced HRQoL outcomes. Lowest scores were obtained from categories including limitations due to physical role and fatigue. Low scores were associated with unemployment, mental cognition, sensory and sleep disturbances, gastrointestinal upset, cardiovascular abnormalities, changes in body temperature and flu-like symptoms. The evidence of this investigation provides confirmation of the negative effects ME/CFS has on HRQoL. Future research should examine the role of ME/CFS symptoms and demographic factors using prospective studies.

**Limitations of the study**

The limitations of this investigation reported by the authors are as follows: (i) weight and height were self-reported; (ii) medical history, symptom presentation and quality of life responses were self-reported; (iii) Australian population norms used as comparative data were published 25 years ago and (iv) variations of symptom severity were not analysed with quality of life scores.

**Availability of data and material**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Acknowledgements** We wish to acknowledge the ongoing support of the Australian ME/CFS community. The authors wish to acknowledge the contribution of Associate Professor Joshua Byrnes for his advice and assistance regarding the statistics for this manuscript.

**Author contributions** DS and SMG provided the research design for this manuscript and supervised the construction of this manuscript. JS wrote and distributed the questionnaire used to collect data for this manuscript. NEF performed data analysis, interpretation of results and drafting of this manuscript. All authors were involved in revision of drafts and have read and approved the final version.

**Funding** This study was supported by the Mason Foundation, McCusker Charitable Foundation, Stafford Fox Medical Research Foundation, Mr Douglas Stutt, Alison Hunter Memorial Foundation, Buxton Foundation, Blake Beckett Trust, Henty Donation, and the Change for ME Charity.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no competing interests.

**Ethical approval** This study was approved by Griffith University Human Research Ethics Committee (HREC reference number MSC0413).

**Informed consent** All participants provided consent prior to completing the survey reported in this study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Carruthers, B. M., van de Sande, M. I., De Meirleir, K. L., Klimas, N. G., Broderick, G., Mitchell, T., et al. (2011). Myalgic encephalomyelitis: International consensus criteria. *Journal of Internal Medicine, 270, 327–338.*

2. Bruberg, K. G., Føhnhus, M. S., Larun, L., Flottorp, S., & Malterud, K. (2014). Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): A systematic review. *British Medical Journal Open, 4, e003973.*

3. Fukuda, K., Straus, S. E., Hickie, I., Sharpe, M. C., Dobbins, J. G., & Komaroff, A. (1995). The chronic fatigue syndrome: A comprehensive approach to its definition and study. *Journal of Chronic Fatigue Syndrome, 1, 67–84.*

4. Carruthers, B. M., Jain, A. K., De Meirleir, K. L., Peterson, D. L., Klimas, N. G., Lerner, A. M., et al. (2003). Myalgic encephalomyelitis/chronic fatigue syndrome: Clinical working case definition, diagnostic and treatment protocols. *Journal of Chronic Fatigue Syndrome, 11, 7–115.*

5. Johnston, S., Brenu, E. W., Staines, D., & Marshall-Gradisnik, S. (2013). The prevalence of chronic fatigue syndrome/myalgic encephalomyelitis: A meta-analysis. *Clinical Epidemiology, 5, 105.*

6. Pendergrast, T., Brown, A., Sunnquist, M., Jantke, R., Newton, J. L., Strand, E. B., et al. (2016). Housebound versus nonhousebound patients with myalgic encephalomyelitis and chronic fatigue syndrome. *Chronic Illness, 12, 292–307.*

7. Friedberg, F., & Jason, L. A. (1998). Understanding chronic fatigue syndrome: An empirical guide to assessment and treatment. *Washington, DC: American Psychological Association.*

8. Joyce, J., Hotopf, M., & Wessely, S. (1997). The prognosis of chronic fatigue and chronic fatigue syndrome: A systematic review. *QJM: Monthly Journal of the Associations of Physicians, 90, 223–233.*

9. Ware, J. E., Jr. (2000). SF-36 health survey update. *Spine, 25, 3130–3139.*

10. Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. *Medical Care, 30, 473–483.*

11. Reeves, W. C., Wagner, D., Nisenbaum, R., Jones, J. F., Gurbaxani, B., Solomon, L., et al. (2005). Chronic fatigue syndrome—A clinically empirical approach to its definition and study. *BMC Medicine, 3, 19.*

12. Hays, R. D., & Morales, L. S. (2001). The RAND-36 measure of health-related quality of life. *Annals of Medicine, 33, 350–357.*

13. A.B.O S. National Health Survey - SF36 Population Norms. Aus Gov Canberra 1997.

14. Johnston, S. C., Brenu, E. W., Hardcastle, S. L., Huth, T. K., Staines, D. R., & Marshall-Gradisnik, S. M. (2014). A comparison of health status in patients meeting alternative definitions for chronic fatigue syndrome/myalgic encephalomyelitis. *Health and Quality of Life Outcomes, 12, 64.* https://doi.org/10.1186/1747-7525-12-64.

15. Jason, L., Brown, M., Evans, M., Anderson, V., Lerch, A., Brown, A., et al. (2011). Measuring substantial reductions in functioning in patients with chronic fatigue syndrome. *Disability and Rehabilitation, 33, 589–598.* https://doi.org/10.3109/09638288.2010.503256.

16. Reyes, M., Nisenbaum, R., Hoaglin, D. C., Unger, E. R., Emmons, C., Randall, B., et al. (2003). Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. *Archives of Internal Medicine, 163, 1530–1536.* https://doi.org/10.1001/archinte.163.13.1530.

17. Lindal, E., Stafánsson, J. G., & Bergmann, S. (2002). The prevalence of chronic fatigue syndrome in Iceland—A national comparison by gender drawing on four different criteria. *Nordic Journal of Psychiatry, 56, 273–277.* https://doi.org/10.1080/080394802026042769.

18. Jason, L. A., Richman, J. A., Rademaker, A. W., Jordan, K. M., Plioplys, A. V., Taylor, R. R., et al. (1999). A community-based study of chronic fatigue syndrome. *Archives of Internal Medicine, 159, 2129–2137.*

19. Reyes, M., Gary, H. E., Dobbins, J. G., Randall, B., Steele, L., Fukuda, K., et al. (1997). Surveillance for chronic fatigue syndrome—four U.S. cities, September 1989 through August 1993. *Morbidity and Mortality Weekly Report: CDC Surveillance Summaries, 46, 1–13.*

20. Bazelmans, E., Verouwen, J. H., Swanink, C. M., Fennis, J. F., Galama, J. M., van Weel, C., et al. (1999). Chronic fatigue syndrome and primary fibromyalgia syndrome as recognized by GPs. *Family Practice, 16, 602–604.* https://doi.org/10.1093/fampra/16.6.602.

21. Asadi-Lari, M., Tamburini, M., & Gray, D. (2004). Patients’ needs, satisfaction, and health related quality of life: Towards a comprehensive model. *Health and Quality of Life Outcomes, 2, 32.* https://doi.org/10.1186/1477-7525-2-32.

22. Nijs, J., Van de Putte, K., Louckx, F., & De Meirleir, K. (2005). Employment status in chronic fatigue syndrome. A cross-sectional study examining the value of exercise testing and self-reported measures for the assessment of employment status. *Clinical Rehabilitation, 19, 895–9.* https://doi.org/10.1191/0269215505cr882oa.

23. Rimbaut, S., Van Gute, C., Van Brabander, L., & Vanden, B. L. (2016). Chronic fatigue syndrome—An update. *Acta Clinica Belgica, 71, 273–280.* https://doi.org/10.1080/17843286.2016.1196862.

24. Jason, L. A., Benton, M. C., Valentine, L., Johnson, A., & Torres-Harding, S. (2008). The Economic impact of ME/CFS: Individual and societal costs. *Dynamic Medicine, 7, 6.* https://doi.org/10.1186/1477-5918-7-6.

25. Chronic Fatigue Syndrome: A Toolkit for Providers n.d. 17.

26. Flores, S., Brown, A., Adeoye, S., Jason, L. A., & Evans, M. (2013). Examining the impact of obesity on individuals with chronic fatigue syndrome. *Workplace Health & Safety, 61, 299–307.* https://doi.org/10.1177/15670991306100705.

27. Nacul, L. C., Lacerda, E. M., Campion, P., Pheby, D., de Drachler, M. L., Leite J. C., et al. (2011). The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers. *BMC Public Health, 11, 402.* https://doi.org/10.1186/1471-2458-11-402.

28. Jason, L. A., Sunnquist, M., Brown, A., Evans, M., Vernon, S. D., Furst, J., et al. (2014). Examining case definition criteria for chronic fatigue syndrome and myalgic encephalomyelitis. *Fatigue Biomedicine & Health Care, 2, 40–56.* https://doi.org/10.1080/21648146.2013.862993.

29. Brown, A. A., Evans, M. A., & Jason, L. A. (2013). Examining the energy envelope and associated symptom patterns in chronic fatigue syndrome: Does coping matter? *Chronic Illness, 9, 302–311.* https://doi.org/10.1177/174395313478220.

30. Brown, M. M., & Jason, L. A. (2007). Functioning in individuals with chronic fatigue syndrome: Increased impairment with co-occurring multiple chemical sensitivity and fibromyalgia. *Dynamic Medicine, 6, 6.* https://doi.org/10.1186/1476-5918-6-6.

31. Buchwald, D., Pearlman, T., Umali, J., Schmaling, K., & Katon, W. (1996). Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals. *American Journal of Medicine, 101, 364–370.* https://doi.org/10.1016/S0002-9343(96)00234-3.

32. Falk Hvidberg, M., Brinth, L. S., Olesen, A. V., Petersen, K. D., & Ehlers, L. (2015). The health-related quality of life for patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *PLoS ONE, 10, e0132421.* https://doi.org/10.1371/journal.pone.0132421.

33. Bassi, N., Amital, D., Amital, H., Doria, A., & Shoenfeld, Y. (2008). Chronic fatigue syndrome: Characteristics and possible causes for its pathogenesis. *The Israel Medical Association Journal, 10, 79.*

34. Bested, A. C., & Marshall, L. M. (2015). Review of Myalgic encephalomyelitis/chronic fatigue syndrome: An evidence-based
approach to diagnosis and management by clinicians. *Reviews on Environmental Health, 30*, 223–249. https://doi.org/10.1515/reveh-2015-0026.

35. Roberts, D. (2018). Chronic fatigue syndrome and quality of life. *Patient Related Outcome Measures, 9*, 253–262. https://doi.org/10.2147/PROM.S155642.

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.